Announcements Trials
Browse Landscape

Phase

Phase 2 9Phase 3 5Phase 1 3Phase NA 2

Status

Active not recruiting 2Suspended 1

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Other solid neoplasm 1Gynecologic 1Genitourinary 1Breast 1

Conditions

Uterine Cervical Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Ovarian Neoplasms 5Cholangiocarcinoma 5Squamous Cell Carcinoma of Head and Neck 4Pancreatic Neoplasms 4Small Cell Lung Carcinoma 3Prostatic Neoplasms 3Neuroblastoma 3Lung Neoplasms 3Gallbladder Neoplasms 3Fallopian Tube Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Mesothelioma, Malignant 2Klatskin Tumor 2Ganglioneuroblastoma 2Colorectal Neoplasms 2Carcinoma, Transitional Cell 2Breast Neoplasms 2Adenocarcinoma of Lung 2Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Testicular Neoplasms 1Seminoma 1Sarcoma 1Pinealoma 1

Interventions

Radiotherapy 39pembrolizumab 37Carboplatin 37Cisplatin 34Paclitaxel 26Pemetrexed 24Docetaxel 18Nivolumab 17Magnetic Resonance Spectroscopy 17Gemcitabine 17Bevacizumab 17Specimen Handling 16Cyclophosphamide 15osimertinib 14Radiation 13Irinotecan 13Etoposide 13Erlotinib Hydrochloride 12durvalumab 11Topotecan 10Cetuximab 10Radiosurgery 9Immunoglobulin G 8Fluorouracil 8Everolimus 8Disulfides 8Celecoxib 8fludarabine 7Taxes 7Ipilimumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Lung Neoplasms × Platinum × Clear all
NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
74 enrolled
BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT05403723 2026-02-19

Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC

University of Maryland, Baltimore

Phase 1 Suspended
50 enrolled
Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT03567642 2025-07-03

A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers

Memorial Sloan Kettering Cancer Center

Phase 1 Active not recruiting
11 enrolled
Thoracic

Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡